OBIO vs. DCTH, RXST, DRTS, CARL, NPCE, SNWV, TCMD, BWAY, SMTI, and SI
Should you be buying Orchestra BioMed stock or one of its competitors? The main competitors of Orchestra BioMed include Delcath Systems (DCTH), RxSight (RXST), Alpha Tau Medical (DRTS), Carlsmed (CARL), NeuroPace (NPCE), Sanuwave Health (SNWV), Tactile Systems Technology (TCMD), Brainsway (BWAY), Sanara MedTech (SMTI), and Shoulder Innovations (SI). These companies are all part of the "medical equipment" industry.
Orchestra BioMed vs. Its Competitors
Delcath Systems (NASDAQ:DCTH) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.
Delcath Systems has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Orchestra BioMed has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.
In the previous week, Delcath Systems had 4 more articles in the media than Orchestra BioMed. MarketBeat recorded 5 mentions for Delcath Systems and 1 mentions for Orchestra BioMed. Delcath Systems' average media sentiment score of 0.27 beat Orchestra BioMed's score of -0.71 indicating that Delcath Systems is being referred to more favorably in the media.
Delcath Systems currently has a consensus price target of $24.50, indicating a potential upside of 126.85%. Orchestra BioMed has a consensus price target of $13.50, indicating a potential upside of 394.51%. Given Orchestra BioMed's higher possible upside, analysts plainly believe Orchestra BioMed is more favorable than Delcath Systems.
Delcath Systems has a net margin of 3.18% compared to Orchestra BioMed's net margin of -2,367.49%. Delcath Systems' return on equity of 6.91% beat Orchestra BioMed's return on equity.
61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are owned by institutional investors. 17.4% of Delcath Systems shares are owned by insiders. Comparatively, 8.1% of Orchestra BioMed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Delcath Systems has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.
Summary
Delcath Systems beats Orchestra BioMed on 14 of the 17 factors compared between the two stocks.
Get Orchestra BioMed News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Orchestra BioMed Competitors List
Related Companies and Tools
This page (NASDAQ:OBIO) was last updated on 10/7/2025 by MarketBeat.com Staff
